Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference (August 2026)
14 slides from Immuron's conference presentation, Aug 19, 2026
Slide 1: Immuron CEO presentation at Emerging Growth Conference
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia, August 19, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting at the Emerging Growth Conference on Wednesday 19th August 2026 (4
Slide 2: Immuron Platform Technology
Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine
Slide 3: References and IBS market information
them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone else. To learn more please check: www.proibs.eu. Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to
Slide 4: Steven Lydeamore, Chief Executive Officer
NASDAQ: IMRN ASX: IMC For personal use only Investor Presentation Steven Lydeamore Chief Executive Officer 19 August 2026
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 6: Immuron integrated biopharmaceutical company overview
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases For personal use only Technology Research & Technology Platform Development Global Corporate Platform Safe and pot
Slide 7: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview For personal use only Two commercial products: Travelan® (traveler’
Slide 8: Continued strong sales growth
Continued strong sales growth Global For personal use only + FY2026 AUD$7.7 million up 6% on prior year Australia + FY2026 AUD$5.8 million up 10% on prior year North America + FY2026 AUD$1.9 million down 5% on prior year + USA FY2026 AUD$1.8 million up 7% on prior year; up 13% in USD + Canada FY2026
Slide 9: Immuron strategic reset provides clearer path to profitability
Immuron strategic reset provides clearer path to profitability Immuron has taken a strategic decision to partner clinical assets IMM-124E and IMM-529 for development and commercialization. For personal use only • IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: trave
Slide 10: IMM-529: A First-in-Class Triple-Action CDI Biologic
IMM-529: A First-in-Class Triple-Action CDI Biologic The Opportunity: IMM-529 is an oral, non-systemic biological (hyperimmune bovine colostrum) for treatment and prevention of primary and recurrent Clostridioides difficile infection (CDI). Unlike antibiotics, IMM-529 eliminates For personal use onl
Slide 11: IMM-529 Market Potential
IMM-529 Market Potential The Disease: C. difficile is the leading cause of healthcare-associated For personal use only infection causing 400,000 cases and 30,000 deaths in the US annually Disease spectrum: • Mild-to-moderate: Watery persistent diarrhea, cramping • Severe/Pseudomembranous Colitis (PM
Slide 12: IMM-529 Deal Potential
IMM-529 Deal Potential Licensor / Asset Stage at Year Licensee / Acquirer Licensed Asset Financial terms (public) Status update (as of March 2026) Owner deal For personal use only Asset sale signed Aug 2024 (public reporting FDA approved (Apr 2023) and commercialized by VOWST (SER-109) indicates dea
Slide 13: Institutional Investor Snapshot FY2026
IMMURON LIMITED (ASX:IMC / Nasdaq:IMRN) | Institutional Investor Snapshot FY2026 Revenue Market Cap. Cash Pipeline A$7.7m FY26 A$10.7m A$10.0m 2 Assets 10 August 2026 Partnering focus For personal use only +6% YoY @31 Dec 26 ; 24-month runway Investment Catalysts (12-18 months) Risk / Reward Assessm
Slide 14: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172